The “Biopsy Breast Modified Radical Mastectomy ER PR HER2NEU KI67 Test” is a comprehensive diagnostic evaluation performed on breast tissue samples, typically obtained during a modified radical mastectomy. This type of mastectomy involves the surgical removal of the breast tissue and some of the lymph nodes under the arm while sparing the chest muscles. The test focuses on analyzing several critical biomarkers that are pivotal in understanding breast cancer characteristics and guiding treatment strategies.

1. **ER (Estrogen Receptor)**: This test measures the presence of estrogen receptors in the cancer cells. Breast cancers that are ER-positive depend on estrogen to grow, and treatments that lower estrogen levels or block estrogen receptors can be effective.

2. **PR (Progesterone Receptor)**: Similar to the ER test, this evaluates the presence of progesterone receptors in the cancer cells. PR-positive cancers can also be treated with hormone-blocking therapies.

3. **HER2/neu**: HER2 is a protein that promotes the growth of cancer cells. In about one of every five breast cancers, the cancer cells make an excess of HER2 due to a gene mutation. HER2-positive breast cancers may be more aggressive but may respond to targeted therapies.

4. **Ki-67**: This is a marker of cell proliferation. Ki-67 levels indicate how quickly breast cancer cells are dividing and growing. Higher levels of Ki-67 suggest a more aggressive cancer that may respond differently to certain treatments.

The test is conducted at DNA Labs UAE, a leading laboratory known for its advanced diagnostic capabilities. The cost of this comprehensive analysis is 3090 AED. By assessing these markers, healthcare providers can tailor a more precise and effective treatment plan for breast cancer patients, enhancing the chances of a successful outcome. This test is crucial for making informed decisions about hormone therapy, chemotherapy, and targeted therapy, thereby significantly impacting the patient’s treatment journey and prognosis.